SCHEMBL6764893

SCHEMBL6764893

CC(O)(CS(=O)(=O)c1ccc(NC(=O)c2cccc(N)c2)cc1)C(=O)NO

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 3/20 0.50
CYP3A4 P08684 3/20 0.47
CYP2C19 P33261 3/20 0.47
CYP2C9 P11712 2/20 0.47
CYP2D6 P10635 1/20 0.47
HDAC8 Q9BY41 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
STAT3 P40763 1/20 0.46
ALDH1A1 P00352 2/20 0.45
HPGD P15428 1/20 0.45
PRMT1 Q99873 1/20 0.44
KDM4E B2RXH2 1/20 0.44
CNR1 P21554 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6764633 0.88 NPC1 (0.52) CYP3A4CYP2C19CYP2C9CYP2D6HDAC8
SCHEMBL6768091 0.87 MAPT (0.53) CYP3A4CYP2C19CYP2C9CYP2D6HDAC8
SCHEMBL6768704 0.87 CYP2C19 (0.50) CYP3A4CYP2C19CYP2C9CYP2D6HDAC8
SCHEMBL6764639 0.87 PRMT1 (0.55) CYP3A4CYP2C19CYP2C9CYP2D6ALDH1A1
SCHEMBL6764878 0.85 TP53 (0.56) ALDH1A1HPGDKDM4EMEN1KMT2A
SCHEMBL6768589 0.82 AR (0.46) CYP3A4CYP2C19CYP2C9CYP2D6ALDH1A1
SCHEMBL6764641 0.80 MAPT (0.54) CYP3A4CYP2C19CYP2C9CYP2D6HDAC8
SCHEMBL6764678 0.77 ENPP1 (0.53) CYP3A4CYP2C19CYP2C9CYP2D6HDAC8
SCHEMBL7084881 0.77 PTGS1 (0.55) PTGS1CYP3A4CYP2C9HDAC8HDAC6
SCHEMBL6767619 0.77 CYP2C19 (0.55) CYP3A4CYP2C19CYP2C9CYP2D6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6716844-B2 ENZYME INHIBITORS; ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS PHARMACIA CORPORATION 2004-04-06 US disclosed
EP-0984959-B1 AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS PHARMACIA CORP (US) 2003-09-24 EP disclosed
US-20020173508-A1 Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds PHARMACIA CORPORATION 2002-11-21 US disclosed
US-6362183-B1 PROTEASE INHIBITORS; RHEUMATIC DISEASES; ANTITUMOR AGENTS G. D. SEARLE & COMPANY 2002-03-26 US disclosed
EP-0984959-A4 AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS MONSANTO CO (US) 2001-05-02 EP disclosed
EP-0984959-A1 AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS MONSANTO COMPANY (US) 2000-03-15 EP disclosed
WO-1998039326-A1 AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS MONSANTO COMPANY (US) 1998-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020173508-A1 Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds MMP1, MMP2, MMP3 PTGS1 363/4885CYP3A4 2250/4885CYP2C19 2259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.